Pazopanib
From Kidney Cancer Resource
Contents |
Overview
Pazopanib was previously known as GW786034 & produced by Glaxo Smith Kline
- N I C E Appraisal Details - Click here
Renal cell carcinoma (second line metastatic) - pazopanib Pazopanib for the second line treatment of metastatic renal cell carcinoma
Status: In progress Expected date of issue: January 2011 Wave: CRS1 Process: STA Notes: Cancer reform strategy Batch 1
Topic area: Cancer Urogenital
Project team | Schedule | Stakeholders | Key documents
NICE project team Executive lead: TBC Technical lead: TBC Communications manager: TBC Project manager: Christopher Feinmann Top
Provisional schedule
Closing date for evidence submission: 13 May 2010
First appraisal committee meeting: 11 August 2010
Details
The Mechanism of Action is as an Angiogenesis inhibitor, VEGF1, VEGF2, VEGF3, c-KIT, PDGFR beta
Aimed to Target VEGFRs, c-KIT, PDGFR beta
For Classes - Small Molecule
MOA Classes - Angiogenesis inhibitor/split kinase
About Pazopanib
Pazopanib is an investigational, oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-kit. Pazopanib is currently in Phase III development for the treatment of advanced or metastatic RCC, after completing patient enrollment several months ahead of schedule, and is also being studied in a number of other trials across various tumor types.
Safety considerations
In more than 1000 patients treated to date with Pazopanib in clinical trials, serious but uncommon (<1%) reports of bowel perforation, myocardial infarction/angina and cerebrovascular accidents/transient ischemic attacks have been reported. The most common laboratory abnormality was an elevation in liver transaminase which occurred as an asymptomatic, reversible event.
Fact Sheet from Glaxo Smith Kline
Articles
Click here for 2009 Articles
MedicalNewsToday (KC) 11-Jun-07
Comments
Clinical Trials have been ongoing in the UK over the past 2 years. entry now closed, full results awaited.
References
|
Disclaimer
Kidney Cancer Resource (KCR) is not influenced by sponsors. The information contained herein is not intended as a substitute for the advice of an appropriately qualified and licensed physician or other licensed health care provider. The information provided here is for educational and information purposes only. Early accurate Diagnosis (Dx.) saves lives. Please check with a physician if you suspect you are ill, never ignore Symptoms. To help your health care specialist make an accurate Diagnosis please keep notes of dates, times and details of your Symptoms. We are not offering medical advice nor do we consider links, individuals or articles accessed through this site to be offering medical advice.
E&OE - Errors & Omissions Excepted
As much of the information posted on this Web Site for peoples convenience is of a medical or technical nature, and may be a matter of life or death the E&OE is a Disclaimer showing that to the best of our ability information is accurate and correctly written or transcribed. Before acting on information on this site you are responsible for checking it with your relevant medical team. We can not be held responsible for any Errors & Omissions made; nor for information on links and articles provided in good faith.
